文献速递肝胆胰外科胃肠外科围术期管理与 ERAS

不可切除结直肠癌肝转移肝移植全肝切除标本中隐匿癌高发

The High Incidence of Occult Carcinoma in Total Hepatectomy Specimens of Patients Treated for Unresectable Colorectal Liver Metastases With Liver Transplant.
PubMed 文献 · Ann Surg · 2023-01-24

该回顾性研究纳入14例因不可切除结直肠癌肝转移接受肝移植的患者,中位肿瘤数11个,中位化疗24周期,肝动脉灌注5例(35.7%)。病理显示11例(78.6%)存在存活肿瘤,9例(64.2%)有术前未诊断的转移灶,7例影像学完全缓解者中4例(57.1%)仍有存活癌。结论:影像学完全缓解不能可靠预测病理学完全缓解。

要点

  • 影像学完全缓解者中57.1%全肝切除标本仍见存活癌。
  • 78.6%患者全肝切除标本存在存活肿瘤。
  • 64.2%患者有术前未诊断的转移灶,至少22个未计入存活肿瘤。

核心结论

  • 影像学完全缓解不能可靠预测病理学完全缓解。
  • 对不可切除结直肠癌肝转移,全肝切除联合肝移植可防止隐匿性病变进展。

研究设计与样本

  • 回顾性研究,纳入2个中心14例因结直肠癌肝转移接受肝移植的患者。
  • 对肝移植前后肿瘤数目及活力进行影像学与病理学关联分析。

主要发现

  • 诊断时中位肿瘤数目11个(四分位距4-23)。
  • 中位化疗周期24个(四分位距16-37)。
  • 肝动脉灌注5例(35.7%),手术切除6例(42.9%),局部区域治疗5例(35.7%)。
  • 肝移植指征为不可切除8例(57.1%),肿瘤治疗继发肝衰竭6例(42.9%)。
  • 肝移植前氟脱氧葡萄糖高摄取肿瘤7例(50%),影像学完全缓解7例(50%)。

临床怎么用

  • 对不可切除结直肠癌肝转移患者,影像学完全缓解不应视为病理学完全缓解。
  • 全肝切除联合肝移植可作为防止隐匿性病变进展的治疗选择。

局限性

  • 回顾性研究,样本量小(14例),来自2个中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the rate of occult carcinoma deposits in total hepatectomy specimens from patients treated with liver transplant (LT) for colorectal liver metastases (CRLM). BACKGROUND: Previous studies have shown that patients with CRLM treated with systemic therapy demonstrate a high rate of complete radiographic response or may have disappearing liver metastases. However, this does not necessarily translate into a complete pathologic response, and residual invasive cancer may be found in up to 80% of the disappearing tumors after resection. METHODS: Retrospective review of 14 patients who underwent LT for CRLM, at 2 centers. Radiographic and pathologic correlation of the number of tumors and their viability before and after LT was performed. RESULTS: The median (interquartile range) number of tumors at diagnosis was 11 (4-23). The median number of chemotherapy cycles was 24 (16-37). Hepatic artery infusion was used in 5 patients (35.7%); 6 (42.9%) underwent surgical resection, and 5 (35.7%) received locoregional therapy. The indication for LT was unresectability in 8 patients (57.1%) and liver failure secondary to oncologic treatment in the remaining 6 (42.9%). Before LT, 7 patients (50%) demonstrated fluorodeoxyglucose-avid tumors and 7 (50%) had a complete radiographic response. Histopathologically, 11 patients (78.6%) had a viable tumor. Nine (64.2%) of the 14 patients were found to have undiagnosed metastases on explant pathology, with at least 22 unaccounted viable tumors before LT. Furthermore, 4 (57.1%) of the 7 patients who demonstrated complete radiographic response harbored viable carcinoma on explant pathology. CONCLUSIONS: A complete radiographic response does not reliably predict a complete pathologic response. In patients with unresectable CRLM, total hepatectomy and LT represent a promising treatment options to prevent indolent disease progression from disappearing CRLM.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Chávez-Villa M, Ruffolo LI, Al-Judaibi BM, et al. The High Incidence of Occult Carcinoma in Total Hepatectomy Specimens of Patients Treated for Unresectable Colorectal Liver Metastases With Liver Transplant. Ann Surg. 2023. PMID: 36692112. doi:10.1097/SLA.0000000000005803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。